Navigation Links
Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition

PITTSBURGH, Oct. 4 /PRNewswire-FirstCall/ -- Mylan (NYSE: MYL) announced today that its Vice Chairman and CEO Robert J. Coury is scheduled to ring The Closing Bell(R) on the New York Stock Exchange (NYSE) at 4 p.m. today, Thursday, Oct. 4, 2007, in celebration of the Company's acquisition of Merck Generics. Mylan announced on Tuesday, October 2, that it had completed its acquisition of Merck KGaA's generics business to become one of the largest quality generics and specialty pharmaceuticals companies in the world.

When: Thursday, Oct. 4, 2007, 4 p.m.

Where: New York Stock Exchange, 11 Wall Street, New York City

A live webcast of The Closing Bell (beginning at 3:55 p.m.) will be available on the homepage of

About Mylan Inc.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit

SOURCE Mylan Laboratories Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. Crohns Patient Robert Hill’s greatest achievemen
5. Relapse in Risk Management System Claims the Life of Robertson
6. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
7. Ruling: HIV victim exempted from disclosing condition to partner
8. Closing in on Lethal Heart Rhythm in Young Athletes
9. Closing In On the Breast Cancer Gene
10. Brain Networks Strengthened by Closing Ion Channels
11. China Closing in on US for Highest Number of Web-users
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology: